MYLAN-VERAPAMIL SR 120 MG
VERAPAMIL HYDROCHLORIDE : 120 MG · DIN 02210347 · MYLAN PHARMACEUTICALS ULC
Health Canada status: MARKETED
What is MYLAN-VERAPAMIL SR?
MYLAN-VERAPAMIL SR 120 MG contains VERAPAMIL HYDROCHLORIDE : 120 MG. It is listed in the Health Canada Drug Product Database under DIN 02210347, held by MYLAN PHARMACEUTICALS ULC, supplied as TABLET (EXTENDED-RELEASE) for ORAL administration. Health Canada currently lists it as marketed, status dated 13-Jun-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02210347 |
|---|---|
| Brand name | MYLAN-VERAPAMIL SR |
| Generic / active ingredient | VERAPAMIL HYDROCHLORIDE : 120 MG |
| Manufacturer | MYLAN PHARMACEUTICALS ULC |
| Strength | 120 MG |
| Dosage form | TABLET (EXTENDED-RELEASE) |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C08DA01 VERAPAMIL |
| AHFS class | 24:28.92 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 13-Jun-2022 |
| Original market date | 1996-12-31 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code C08DA01 VERAPAMIL. 5 of 53 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-VERAP TAB 80MG | 80 MG | TABLET | APOTEX INC | MARKETED | DIN 00782483 |
| APO-VERAP TABLET 120MG | 120 MG | TABLET | APOTEX INC | MARKETED | DIN 00782491 |
| ISOPTIN SR | 120 MG | TABLET (EXTENDED-RELEASE) | BGP PHARMA ULC | MARKETED | DIN 01907123 |
| VERAPAMIL HYDROCHLORIDE INJECTION USP | 2.5 MG | LIQUID | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02166739 |
| ALTI-VERAPAMIL - 120MG | 120 MG | TABLET | ALTIMED PHARMA INC. | CANCELLED POST MARKET | DIN 00867373 |
| ALTI-VERAPAMIL - 80MG | 80 MG | TABLET | ALTIMED PHARMA INC. | CANCELLED POST MARKET | DIN 00867365 |
| APO-VERAP SR | 120 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | DORMANT | DIN 02246893 |
| APO-VERAP SR | 180 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | DORMANT | DIN 02246894 |
| APO-VERAP SR | 240 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | DORMANT | DIN 02246895 |
| COVERA-HS | 180 MG | TABLET (EXTENDED-RELEASE) | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 02231676 |
Who else supplies VERAPAMIL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. VERAPAMIL appears in 107 registered pack listings across 13 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.